Search Results
Your search for The ASCO matches 21123 pages
Showing 9701 - 9750The Risks of Drug Approval Based on Shaky Evidence
Two recent publications in The New England Journal of Medicine (NEJM), and the resulting drug approval applications that have already been filed, lead to concern that the basis of medical practice on valid evidence may be corrupted. Each involves statistically shaky analysis leading to a striking...
Sarcoma Coalition Launched as Collaboration of Advocacy Organizations
Those dealing with sarcoma know that resources and support can be difficult to find. Members of the newly formed Sarcoma Coalition are working together to change that. The Sarcoma Coalition is a nonprofit collaboration of sarcoma advocacy organizations from around the country working toward a...
National Brain Tumor Society and Brain Science Foundation Partner to Fund Research in Meningioma
The National Brain Tumor Society, a nonprofit dedicated to the brain tumor community in the United States, recently announced a new partnership with the Brain Science Foundation. Under the terms of the partnership, the organizations have established the Meningioma Research Fund to raise and grant...
Jeffrey Bluestone, PhD, Awarded Distinguished Lectureship
The American Association for Cancer Research (AACR) has awarded the 15th AACR–Irving Weinstein Foundation Distinguished Lectureship to Jeffrey Bluestone, PhD. The award was presented during the 2019 AACR Annual Meeting in Atlanta. Dr. Bluestone is President and Chief Executive Officer of the...
Johns Hopkins Greenberg Bladder Cancer Institute Awards Research Grants to Women’s Bladder Cancer Projects
The Johns Hopkins Greenberg Bladder Cancer Institute awarded research grants to four projects that focus on bladder cancer treatments in women and how biology could offer new targets for cancer therapy.The Institute awards grants of $25,000 to $50,000. David McConkey, PhD, Director of the...
ASCO President-Elect Howard A. Burris III, MD, FACP, FASCO, Gained Leadership Skills From His Experience at West Point
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Howard A. “Skip” Burris III, MD, FACP,...
Stephen J. Forman Awarded Two Bone Marrow Transplantation Honors
Stephen J. Forman, MD, Leader of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, recently received the 2019 DKMS Mechtild Harf Science Award in...
CAR T-Cell Therapy for DLBCL: At the Crossroads of Hype and Reality
In the 20-plus years I have spent in hematologic oncology, I have been fortunate to have a ringside seat to watch “game-changing” advances come into our field—all-trans retinoic acid for acute promyelocytic leukemia, tyrosine kinase inhibitors starting with imatinib for chronic myeloid leukemia,...
EAU 2019: Testosterone Replacement Therapy May Slow Recurrence in Low-Risk Prostate Cancer
Researchers have shown that testosterone replacement may slow the recurrence of prostate cancer in low-risk patients. Findings from the study were presented by Towe et al at the European Association of Urology (EAU) 2019 Congress (Abstract 646). Practitioners have long regarded testosterone as a...
Fred R. Hirsch, MD, PhD, Named Executive Director of New Center for Thoracic Oncology at Mount Sinai
Fred R. Hirsch, MD, PhD, an authority on lung cancer treatment and research, has joined Mount Sinai Health System as Executive Director of the newly created Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai and will also serve as the Richard M. Stein, MD, Joe Lowe, and...
American Skin Association Announces 18 New Grants for Skin Cancer and Disease Research
For more than 3 decades, the American Skin Association (ASA) and its affiliates have funded more than $50 million in grants to address the causes and treatments of melanoma, vitiligo, and psoriasis, as well as other skin diseases, and to search for cures. Recently, the American Skin Association...
EAU 2019: Early Menopause in Smokers May Be Linked to Increased Risk of Bladder Cancer
New research has shown that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer; this higher risk was even more notable in smokers. The study, which looked at health outcomes in more than 220,000 patients, was presented by Abufaraj et al at the European...
Assessing the Clinical Utility of ASCO’s and ESMO’s Value Frameworks
In 2015, ASCO and the European Society for Medical Oncology (ESMO) introduced value frameworks that utilize algorithmic scales to evaluate the clinical benefit of cancer therapies and provide an objective assessment of outcomes and treatment toxicities experienced by patients.1,2 Although the two...
Implementing Personalized Pathways for Cancer Follow-up Care in the United States
A new approach to cancer follow-up care is required to meet the needs of the growing population of cancer survivors in the United States, while also addressing provider shortages and rising costs, according to a new multiagency report. The report—published by Alfano et al in CA: A Cancer ...
Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials
Sumanta K. Pal, MD, of City of Hope, talks about the need for investigators across the country to enroll their patients with rare tumors in clinical trials. He describes a trial he is leading for papillary kidney cancer and how others can join his efforts.
Karim Fizazi, MD, PhD: We Need to Find a Way to Make Cancer Drugs Affordable
Karim Fizazi, MD, PhD, of Gustave Roussy, urges governments, insurers, and pharmaceutical companies to work together in order to find a way to make anticancer drugs affordable and accessible for all patients.
FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More
In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...
Incidence of Nonmelanoma Skin Cancer in Recipients of Multiple Kidney Transplants
The incidence of nonmelanoma skin cancer may be more common in recipients of kidney transplants vs patients on maintenance dialysis. Researchers looked to determine if the risk of nonmelanoma skin cancer is lower during periods of graft loss with a return to dialysis vs during periods of...
Does Postoperative Conformal Radiotherapy Improve Survival in Pediatric Patients With Ependymoma?
Treatment with conformal radiation therapy immediately following surgery in children with ependymoma may greatly improve survival. The findings were published by Merchant et al in the Journal of Clinical Oncology. “Historically, children under the age of 3 with ependymoma have a worse...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
Statement on White House’s FY2020 Budget Proposal by ASCO President Monica M. Bertagnolli, MD, FACS, FASCO
ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, issued the following statement earlier this week: We strongly oppose the White House budget proposal for fiscal year (FY) 2020, which would stall our nation's progress against cancer and impede access to needed care for the millions of...
2019 Thoracic Cancers Symposium: Trends in Use of Prophylactic Cranial Irradiation for Extensive-Stage SCLC
A new survey of radiation oncologists points to a sharp decline in the use of prophylactic cranial irradiation for patients with extensive-stage small cell lung cancer (SCLC), indicating a rapid change in standard practice for the disease following the 2017 publication of a major clinical trial by...
2019 Thoracic Cancers Symposium: Effect of Structured Patient Exposure to the NCCN Guidelines for NSCLC
A new clinical trial found that exposing patients to tailored versions of the National Comprehensive Cancer Network (NCCN®) Guidelines for non–small cell lung cancer (NSCLC) may help drive smoking cessation, testing for potential biomarkers and, for early-stage disease, more...
2019 Thoracic Cancers Symposium: Local Consolidative Therapy and Overall Survival in Oligometastatic NSCLC
A new analysis of patients treated with local consolidative therapy for oligometastatic non–small cell lung cancer (NSCLC) found that the intensive treatment approach is associated with improved overall survival. Local consolidative therapy—consisting of radiation therapy or...
HHS Secretary Appoints Norman E. Sharpless, MD, as FDA Acting Commissioner
Today, the Secretary of Health and Human Services (HHS) Alex M. Azar II appointed Norman E. Sharpless, MD, to be the acting Commissioner of the U.S. Food and Drug Administration (FDA). He will be replacing the current FDA Commissioner, Scott Gottlieb, MD, who announced his resignation on March 5....
FDA Approves Trastuzumab-qyyp in HER2-Overexpressing Breast and Gastric Cancers
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-qyyp (Trazimera), a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...
Lack of Genetic Diversity in Common Cancer Cell Lines
Researchers have found that some commercial cancer cell lines used for laboratory studies have mislabeled ancestry when it comes to minorities. These findings were published by Hooker et al in Cancer Epidemiology, Biomarkers & Prevention. “A lack of diversity is prevalent in every level...
Global Incidence of Undiagnosed Pediatric Cancers
Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study published by Ward et al in The Lancet Oncology. “Our model suggests that nearly one in two children with cancer are never diagnosed and may die untreated,” said lead...
Humanitarian, Cancer Specialist Advocates for Universal Access to Care as a Basic Human Right
There is a plethora of educational books for patients with cancer and their families; advocates and patients themselves write most. Books in this genre often have a difficult time distilling the hard science of oncology into a lay-friendly narrative that keeps the reader engaged from cover to...
We Need Better Screening Methods for Detecting Breast Cancer
MY BREAST CANCER was probably a decade in the making, although I only became aware that there might be a problem in 2014, when I noticed some slight pain in my left breast. A routine mammogram and ultrasound found benign cysts in my dense breasts, which most likely explained the pain, I was told,...
Update on Newer Treatments in Non-Hodgkin Lymphomas
AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), ...
FDA Approves Trifluridine/Tipiracil for Recurrent, Metastatic Gastric and GEJ Adenocarcinoma
ON FEBRUARY 22, the U.S. Food and Drug Administration approved trifluridine/tipiracil tablets (Lonsurf)—a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor—for adult patients with metastatic gastric or gastroesophageal junction...
FDA Grants Accelerated Approval to Atezolizumab/Nab-Paclitaxel; Regular Approval Contingent on Confirmatory Trials
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for the treatment of adults with unresectable, locally advanced or metastatic, programmed cell death ligand 1 (PD-L1)-positive ...
Omega-3 Fatty Acids
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, explore the use of omega-3 fatty acids, which have...
Roy L. Silverstein, MD, Begins Term as 2019 ASH President
ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Dr. Silverstein is Chairman of the Department of...
Health-Care Fraud Prosecutions Are on the Rise
Prosecuting health-care fraud is a top priority for the U.S. Department of Justice (DOJ) and other federal government agencies.1,2 After all, the government earns a $6 return for every $1 that it spends on enforcement. In December 2018, the DOJ announced that it had obtained more than $2.5 billion...
Reshaping the Treatment Landscape in Refractory Multiple Myeloma
THE TREATMENT approaches for multiple myeloma, both newly diagnosed and relapsed disease, continue to undergo major transformation as new agents and combinations are being introduced.1 This change has been driven by the introduction of novel drug classes such as monoclonal antibodies, as well as...
ASH President Roy Silverstein, MD, Issues Comment on Maintenance of Certification Recommendations Draft
RECENTLY, THE American Society of Hematology (ASH) submitted feedback on draft recommendations for reforming Maintenance of Certification (MOC) to a commission appointed by the American Board of Medical Specialties (ABMS) and other entities. The “Vision Commission” released a report of its draft...
Although Evidence Is Clear That Lung Cancer Screening Saves Lives, Adoption Rates Remain Low
The findings of the National Lung Screening Trial (NLST), reported in 2011, revealed that participants who received low-dose helical computed tomography (CT) scans had a 20% lower risk of dying of lung cancer than participants who received standard chest x-rays. Despite these results,...
Robin Zon, MD, FACP, FASCO, Elected President of Michiana Hematology Oncology
MICHIANA HEMATOLOGY Oncology has announced that Robin Zon, MD, FACP, FASCO, has been elected President by its shareholders. In her new role as President, Dr. Zon will oversee and maintain leadership of the practice. Dr. Zon is a member of ASCO and was awarded Fellow status; with ASCO, she served...
Michael Cabana, MD, MA, MPH, and Lori Pbert, PhD, Join USPSTF
THE U.S. PREVENTIVE Services Task Force (Task Force) announced the addition of two new members: Michael Cabana, MD, MA, MPH, and Lori Pbert, PhD. Both were appointed to serve 4-year terms, which began in January 2019. Dr. Cabana is Professor of Pediatrics, Epidemiology, and Biostatistics and a...
Position Paper Addresses Shortages of Chemotherapy and Supportive Care Agents for Pediatric Oncology Patients
Shortages of essential chemotherapy drugs for children undergoing cancer treatment have been an increasingly frequent obstacle for patients and hospitals in the United States. These shortages can result in increased medication errors, delayed administration of life-saving therapy, inferior...
New Patient Resource: NCCN Guidelines for Patients With Squamous Cell Skin Cancer
The National Comprehensive Cancer Network® (NCCN) has published a new book of patient information that explains prevention, diagnosis, and treatment for squamous cell skin cancer. Squamous cell and basal cell skin cancers are responsible for about 5 million annual incidents of nonmelanoma...
Patients With Breast Cancer Provide Recommendations to Ease Financial Toxicity
A qualitative study yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services, and financial assistance to reduce long-term, breast cancer–related economic burden. The study was published by Dean et al in Cancer. Unique...
Is the Presence of Nevi on Extremities a Risk Factor for Melanoma and Nonmelanoma Skin Cancers?
The presence of nevi is an established risk factor for melanoma. In light of this, researchers examined the association between the presence of nevi on extremities and the risk of melanoma and nonmelanoma skin cancers. Their findings were published by Wei et al in the Journal of the American...
A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma
A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be...
Effect of Adjuvant Treatment for Early Testicular Cancer on Reproductive Potential
Men with early-stage testicular cancer can safely receive one course of adjuvant chemotherapy or radiotherapy without it having a long-term effect on their reproductive potential, according to a study published by Weibring et al in Annals of Oncology. Although it is known already that several...
FDA Commissioner Scott Gottlieb, MD, Resigns
On March 5, 2019, Scott Gottlieb, MD, announced his resignation as Commissioner of the U.S. Food and Drug Administration (FDA), a post he began in 2017. Dr. Gottlieb’s resignation will be effective next month. In a resignation letter to Alex M. Azar II, Secretary of Health and Human Services ...
FDA Pipeline: Updates on Treatments for Cervical Cancer, Myelofibrosis, Chemotherapy-Induced Nausea and Vomiting, and More
The FDA recently issued announcements on a Fast Track designation, a Priority Review, two supplemental new drug applications, an investigational new drug application, and a marketing clearance. The agency also released a safety communication on cancer-related surgery. Fast Track Designation for...
Effect of Affordable Care Act’s Medicaid Expansion on Colorectal Cancer Screening and Survival in Kentucky
Kentucky has been one of the most successful states in reducing its uninsured rate, which happened in part through the Affordable Care Act’s Medicaid expansion that took effect on January 1, 2014. In the past, Kentucky has reported low rates of colorectal cancer screening, and has ranked ...
